SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

DLocal Ltd. engages in the business of simplifying and redefining online payments experience. It focuses on processing payment transactions which enables merchants to get paid from customers and to make payments to customers in emerging markets. The company was founded by Andrés Bzurovski Bay and Sergio Enrique Fogel Kaplan in 2016 and is headquartered in Montevideo, Uruguay.

DLocal Limited - Ordinary Shares Class A

DLocal Limited

DLocal Limited is seeing a massive surge in investor activity and bullish sentiment following a strong earnings report that showcased double-digit revenue growth and upbeat guidance. The community is actively discussing the stock's potential for a short squeeze, citing high short interest and institutional accumulation as primary drivers for further upside.

Trio-Tech International engages in the provision of third-party semiconductor testing and burn-in services. It operates through the following segments: Semiconductor Back-End Solutions (SBS) and Industrial Electronics. The SBS segment is focused on the sale of burn-in and reliability test equipment used in the back-end manufacturing processes of semiconductors. Its equipment includes burn-in systems, burn-in boards, and related equipment that is used in the testing of structural integrity of integrated circuits. The Industrial Electronics segment consists of designing, manufacturing, and distributing a range of tests, processes, and other equipment used in the manufacturing processes of customers in various industries in the consumer and industrial market. The company was founded in 1958 and is headquartered in Los Angeles, CA.

Trio-Tech International

Trio-Tech International is trending as investors rally around the company's surging revenue, which is being driven by critical demand for its semiconductor reliability testing services within the AI and electric vehicle sectors. The community is actively discussing the potential for a valuation re-rating, often drawing comparisons to industry peers like AEHR and highlighting the company's recent expansion in Malaysia as a key indicator of long-term growth.

Rayls is a Layer-1 blockchain ecosystem designed for financial institutions to bridge traditional finance (TradFi) and decentralized finance (DeFi). Developed by Parfin, Rayls combines a public chain, private networks, and institutional privacy nodes into a unified infrastructure that supports compliant, scalable, and privacy-preserving asset tokenization and settlement. Its architecture connects regulated banks and payment systems with public DeFi liquidity while maintaining confidentiality through the Rayls Enygma privacy protocol. The network enables tokenization of real-world assets, CBDCs, and stablecoins using EVM-compatible technology, fixed USD-pegged gas fees, deterministic finality, and harmful MEV protection.

Rayls

Rayls is generating significant community interest surrounding its recent mainnet launch and tokenomics activation, which investors hope will bridge traditional finance with blockchain utility. While some users are frustrated by recent price volatility and selling pressure, many are actively accumulating tokens in anticipation of potential institutional partnerships and long-term growth.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin (CRO) is seeing heightened community discourse driven by anticipation surrounding potential ETF launches and regulatory developments like the Clarity Act. Investors are actively debating the impact of ongoing token emissions on price performance while simultaneously rallying behind the native Cronos meme coin $MERY, which has gained significant traction due to its strong correlation with $CRO and community-led security narratives.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing heightened volatility as investors weigh the potential long-term impacts of the Clarity Act against immediate market pressure from rising Treasury yields and institutional outflows. While many community members are debating whether this price action represents a healthy shakeout of leveraged positions or a broader cooling of the crypto rally, significant institutional demand continues to frame the long-term outlook.

Ulta Beauty, Inc. engages in the retail of beauty products. The company has one reportable segment, which includes retail stores, salon services, and e-commerce. Its products include makeup, skin care, tools and brushes, fragrance, and bath and body. The company was founded on January 9, 1990 and is headquartered in Bolingbrook, IL.

Ulta Beauty Inc

Ulta Beauty is experiencing significant market volatility as investors weigh strong quarterly earnings and raised full-year guidance against concerns over broader consumer spending trends. The stock remains a focal point for the trading community, drawing intense debate between those betting on long-term growth and those positioning for short-term pullbacks amid macro headwinds.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies Corp. is attracting significant retail interest as investors focus on its specialized tech-integrated approach to the metals supply chain and potential as a domestic rare earth alternative. Community discussions are heavily centered on the stock's extremely low float, which has fueled aggressive price volatility and momentum-driven trading activity following its recent market debut.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is facing significant selling pressure as investors react to surging Treasury yields and heightened inflation concerns fueled by the ongoing energy crisis. The community is actively debating whether current bond levels represent a historic buying opportunity or if structural debt issues and aggressive deficit spending signal further downside for the asset.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPeng is currently in the spotlight as investors weigh its aggressive global expansion and advancements in physical AIincluding proprietary autonomous driving software and roboticsagainst persistent delivery volume concerns and geopolitical headwinds. The community remains polarized, with many retail traders actively buying the dip to capitalize on anticipated long-term breakthroughs, while others express frustration over sustained price volatility and weak short-term performance.

Macy's, Inc. engages in the retail of apparel, accessories, cosmetics, home furnishings, and other consumer goods. The firm's brands include Macy's, Bloomingdale's, and Bluemercury. It offers men's, women's, and children's apparel, women's accessories, intimate apparel, shoes, cosmetics, fragrances, as well as home and miscellaneous products. The company was founded by Rowland H. Macy in 1858 and is headquartered in New York, NY.

Macy`s Inc

Macy's Inc

Macy's Inc. is seeing significant market momentum following a second-quarter earnings report that surpassed analyst expectations, driven by improvements in comparable sales and a successful turnaround strategy centered on store optimization. Investors are closely monitoring the stock as the company navigates potential macro headwinds while attempting to leverage its premium brand portfolio and real estate assets.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The agency explicitly stated that the trial’s current primary endpoint is “not an appropriate endpoint to demonstrate efficacy.”</li><li>As a result, the FDA no longer considers the study to be “pivotal.”</li><li>Top-line data from the 40-patient randomized, controlled study are still expected in August 2026.</li></ul> Longeveron Inc. (LGVN) shares fell 4% in after-hours trading on Friday after the U.S. Food and Drug Administration expressed reservations on the trial design for its cell therapy laromestrocel.Longeveron announced that it held a meeting with the FDA in late March 2026 to discuss the ongoing mid-stage trial of its investigational cell therapy laromestrocel in infants with hypoplastic left heart syndrome (HLHS), a severe, rare congenital heart defect where the left side of a baby's heart is severely underdeveloped and cannot properly pump blood to the body. Though the firm called the meeting ‘constructive’, investors seem more focused on the agency’s reservations about the trial’s design and its potential to support approval.<h2 class="st-heading-2">Meeting Outcomes</h2>The FDA acknowledged that HLHS is a rare, life-threatening congenital heart defect with “significant morbidity and mortality” and a high unmet medical need. However, the agency explicitly stated that the trial’s current primary endpoint is “not an appropriate endpoint to demonstrate efficacy.”Longeveron said it agreed with the FDA’s assessment that the endpoint alone is insufficient. Though the company had hoped to discuss alternative or composite endpoints, the FDA indicated it could not agree to a new primary endpoint while the trial is still ongoing, it said.As a result, the FDA no longer considers the study to be “pivotal” — a designation the agency had previously discussed with the company.The release noted that the FDA is “willing to meet with Longeveron again when the ongoing ELPIS II study is completed to discuss the study results and align on a potential path forward.” Top-line data from the 40-patient randomized, controlled study are still expected in August 2026The agency emphasized that only the most objective clinical measures — all-cause mortality, cardiac transplant-free survival, events of cardiac transplantation, and well-defined major adverse cardiac events (MACE) — would be considered informative for efficacy. Longeveron said it is already capturing those endpoints, along with additional supportive measures.The company plans to submit a revised plan featuring a composite primary endpoint and secondary endpoints for FDA review. It remains “optimistic” that the full dataset, combined with other evidence, will still support an application filing after the August readout.<h2 class="st-heading-2">How Did LGVN Retail Traders React?</h2>On Stocktwits, retail sentiment around LGVN stock improved from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘normal’ levels.A Stocktwits user said that they will take their loss with the company.<stembedurl>https://www.stocktwits.com/Dorps332/message/652803025</stembedurl>Another highlighted the negative takeaways from the meeting.<stembedurl>https://www.stocktwits.com/Biotech_Pharma_Investor/message/652802598</stembedurl><a href="https://stocktwits.com/symbol/LGVN">LGVN stock</a> has fallen 43% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/mrna-stock-clocks-best-day-in-over-two-months-on-early-stage-hantavirus-vaccine-research/cZX2zB5Rego">MRNA Stock Clocks Best Day In Over Two Months On Early-Stage Hantavirus Vaccine Research</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Longeveron, Inc. logo appears on a smartphone screen in this illustration photo in Reno, United States, on January 3, 2025. (Photo Illustration by Jaque Silva/NurPhoto via Getty Images)

LGVN Stock Slips After Hours As FDA Flags Concerns On Rare Heart Defect Trial Design

Though the firm called the meeting ‘constructive’, investors seem more focused on the agency’s reservations about the laromestrocel trial’s design and its potential to support approval.

Equity

Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells

Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells Biotechs Racing to...

A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.

A Key 'Master' Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. A Key 'Master' Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. PR...

Longeveron (LGVN) Q4 2025 Earnings Call Transcript

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...

Longeveron Braces For Q4 Results Following Recent Funding Boost

Longeveron Inc. shares are trading higher Tuesday as investors pivot their focus toward the company's Q4 earnings report, due after the bell.read more...

Longeveron (LGVN) Shares Surge On $30 Million Private Placement Deal

Longeveron shares are trading sharply higher Tuesday afternoon following the announcement of a private placement agreement worth up to $30 million.read more...

Best Biotech Stocks To Keep An Eye On - March 10th

Vertex Pharmaceuticals, BioNTech, Danaher, Longeveron, Moderna, United Therapeutics, and argenex are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech...

<ul class="summary-bullets"><li>The company said that laromestorcel infusions resulted in clinically meaningful, dose-and time-dependent increases in the primary endpoint of the 6-minute walk test compared with placebo.</li><li>The company was evaluating whether its investigational therapy improves physical functioning in 148 ambulatory individuals with frailty.</li><li>The therapy is currently being evaluated in multiple indications including hypoplastic left heart syndrome (HLHS) and Alzheimer’s disease (AD).</li></ul>Shares of Longeveron Inc. (LGVN) rose 7% on Wednesday, before paring back gains, after the company announced positive results from the trial of its investigational therapy in age-related clinical frailty.The company said that intravenous laromestrocel improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo, in a study.LGVN shares traded 9% lower at the time of writing.<h2 class="st-heading-2">Trial Outcomes</h2>The company said that laromestorcel infusions resulted in clinically meaningful, dose-and time-dependent increases in the primary endpoint of the 6-minute walk test compared with placebo. The 6-Minute Walk Test (6MWT) is a submaximal, standardized exercise test measuring the distance a patient can walk on a flat, hard surface in six minutes.“We are highly encouraged by these Phase 2b results that demonstrate the potential of stem cell therapy to improve the condition of patients with aging-related frailty,” <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.longeveron.com/news/News/news-details/2026/Longeveron-Results-of-Phase-2b-Clinical-Trial-Demonstrating-Stem-Cell-Therapy-Improved-Condition-of-Patients-with-Age-Related-Frailty-Published-in-Cell-Stem-Cell/default.aspx">said</a> Joshua M. Hare, Chief Science Officer at Longeveron. “Those with Aging Frailty are disproportionately compromised in their ability to cope with every day and acute stressors, are at high vulnerability to disease and injury, and are at increased risk for poor outcomes and death after surgery.”Laromestrocel, the company’s lead investigational product, is a human bone marrow-derived allogeneic stem cell (MSC) investigational therapy. The company was evaluating whether it improves physical functioning in 148 ambulatory individuals with frailty. The therapy is currently being evaluated in multiple indications including hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), and Pediatric Dilated Cardiomyopathy (DCM).<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around LGVN stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.A Stocktwits user said that positive news from the company never helps the stock price.<stembedurl>https://www.stocktwits.com/Dorps332/message/645856800</stembedurl><a href="https://stocktwits.com/symbol/LGVN">LGVN stock</a> is down by 64% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-odd-shares-tumble-today/cZRyBHbRIGS">Why Did ODD Shares Tumble More Than 50% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty Study

Longeveron said that intravenous laromestrocel improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo.

$LGVN Q1 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.19 up 44.12% YoY
• Reported revenue of $0.4M up 4.46% YoY
• Longeveron expects its cash and cash equivalents as of March 31, 2026, including Private Placement proceeds, will fund operations into the fourth quarter of 2026, but additional financing will be required. Longeveron anticipates continued operating losses and increased spending.

Stocktwits

 Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.19 up 44.12% YoY
• Reported revenue of $0.4M up 4.46% YoY
• Longeveron expects its cash and cash equivalents as of March 31, 2026, including Private Placement proceeds, will fund operations into the fourth quarter of 2026, but additional financing will be required. Longeveron anticipates continued operating losses and increased spending.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.17	--	--	N/A
Q1 '26	-$0.18	-$0.19	-7.04%	MISSED
Q4 '25	-$0.37	-$0.23	37.27%	BEAT
Q3 '25	-$0.25	-$0.39	-52.94%	MISSED
Q2 '25	-$0.35	-$0.33	5.71%	BEAT

LGVN
Longeveron Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '26

Historical Earnings

Latest LGVN News

LGVNLongeveron Inc - Ordinary Shares - Class A